FORM PTO 1449 (modified)	Atty. Docket No. X-15876	Serial No 10/526,960
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	First Applicant Maria-Jesus Blanco-Pillado	
	PCT Application Date: September 17, 2003	Group Art Unit 1624
	US Nat'l Entry Date: March 3, 2005	

U.S. PA	U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No. ¹	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Pages or Relevant Figures Appear	
	AC	US 4,191,771	March 4, 1980	Zimmerman		
	AD	US 4,891,379	January 2, 1990	Zimmerman, et al.		
	AE	US 6,140,352	October 31, 2000	Crowell, et al.		

Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ - Kind Code5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т ⁶
	BI	EP 1 072 592	31 January 2001	Pfizer, Inc.		
	BJ	WO 02/078693	10 October 2002	Eli Lilly and Company		
		NON PAT	TENT LITERAT	URE DOCUME	ENTS	
Examiner Initials*	Cite No. 1	Include name of the author	(in CAPITAL LETTERS erial, symposium, catalog), title of the article (when , etc.), date, page(s), volur	ENTS appropriate), title of the item ne-issue number(s) publisher,	T ⁶
		Include name of the author (book, magazine, journal, s Wentland, et al., "8-C Activity Relationship	(in CAPITAL LETTERS berial, symposium, catalog city and/or count arboxamidocyclazoc s of 2,6-Methano-3-E), title of the article (when , etc.), date, page(s), volur ry where published. ine Analogues: Rede Benzazocines," <u>Bioor</u>	appropriate), title of the item ne-issue number(s) publisher, fining the Structure-	T ⁶
	No. 1	Include name of the author (book, magazine, journal, see Wentland, et al., "8-C Activity Relationship Chemistry Letters, Vowentland, et al., "3-C	(in CAPITAL LETTERS, serial, symposium, catalog city and/or country arboxamidocyclazoc s of 2,6-Methano-3-Ed. 11, pgs. 623-626 (arboxamido Analogu Binding Properties,"), title of the article (when , etc.), date, page(s), volur ry where published. ine Analogues: Rede Benzazocines," <u>Bioor</u> 2001) tes of Morphine and	appropriate), title of the item ne-issue number(s) publisher, fining the Structure-	T ⁶

Examiner	Date Considered	
Signature		

^{**}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to their Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.